Predictors of 12 month continuation of paliperidone long acting injection treatment for schizophrenia: a naturalistic cohort study

被引：0
|
作者：
Whale, R. [1 ]
Pereira, M. [2 ]
Fialho, R. [3 ]
机构：
[1] Brighton & Sussex Med Sch, Div Med Educ, Brighton, E Sussex, England
[2] Univ Coimbra, Fac Psychol & Educ Sci, Coimbra, Portugal
[3] Sussex Partnership NHS Fdn Trust, Neuropharmacol Res, Brighton, E Sussex, England
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
D O I：
10.1016/S0924-977X(14)70843-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.010
引用
收藏
页码：S526 / S527
页数：2
相关论文
共 50 条
  • [41] Improvement of negative symptoms in schizophrenia with paliperidone palmitate: 1-month versus 3-month long-acting injectables
    Mathews, M.
    Gopal, S.
    Singh, A.
    Gogate, J.
    Kim, E.
    Pungor, K.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S101 - S102
  • [42] Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia : A Critical Appraisal
    Garcia-Carmona, Juan Antonio
    Pappa, Sofia
    [J]. DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 113 - 123
  • [43] Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
    Mahlich, Jorg
    Nishi, Masamichi
    Saito, Yoshimichi
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 267 - 272
  • [44] Novel long-acting treatment for schizophrenia based on paliperidone dissolving and implantable microarray patches
    Zhao, Li
    Li, Linlin
    Larran, Eneko
    Paredes, Alejandro J.
    Donnelly, Ryan F.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2024, 204
  • [45] Experience with risperidone long-acting injection: results of a naturalistic observation study
    Deslandes, Paul N.
    Thomas, Arwel
    Faulconbridge, Gwawr M.
    Davies, Wendy C.
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2007, 11 (03) : 207 - 211
  • [46] An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate
    Sliwa, Jennifer Kern
    Savitz, Adam
    Nuamah, Isaac
    Mathews, Maju
    Gopal, Srihari
    Elefant, Erica
    Najarian, Dean
    Alphs, Larry
    [J]. PERSPECTIVES IN PSYCHIATRIC CARE, 2018, 54 (04) : 530 - 538
  • [47] Treatment retention with risperidone long acting injection (RLAI) in European patients with schizophrenia: 12-month interim results from electronic Schizophrenia Treatment Adherence Registry (e-STAR)
    Olivares, J. M.
    Peuskens, J.
    Pecenak, J.
    Tuma, I
    Van Kooten, M.
    Eriksson, L.
    Povey, M.
    Lam, A.
    Zhao, Z.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A290 - A290
  • [48] COST-UTILITY ANALYSIS OF LONG-ACTING PALIPERIDONE IN COMPARISON WITH ORAL RISPERIDONE, ORAL PALIPERIDONE AND LONG-ACTING RISPERIDONE IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE CZECH REPUBLIC
    Kolek, M.
    Duba, J.
    Vesela, S.
    Pasztor, B.
    Doleckova, J.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A459 - A459
  • [49] Long-acting paliperidone injection as a treatment option for interictal psychosis of epilepsy: A case report
    Pinto-Gouveia, Carolina
    Ventura, Fabiana
    Carneiro, Mario
    Mota, David
    Renca, Susana
    Pissarra, Celsa
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2022, 76 (07) : 347 - 348
  • [50] COST-EFFECTIVENESS-ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA: 12 MONTH DATA FROM CZECH REPUBLIC
    Skoupa, J.
    Cerna, V
    Dolezal, T.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A585 - A585
12345